Latest Capecitabine Stories
A study of more than 1,000 patients with colon cancer that had spread to distant sites found that one in eight was treated with at least one drug regimen that was not recommended.
CHICAGO and SAN FRANCISCO, June 4, 2011 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced positive results from a Phase 2 clinical study evaluating single-agent NKTR-102 as a second- and third-line treatment in patients with metastatic breast cancer during the 2011 American Society of Clinical Oncology Meeting (ASCO).
WAYNE, N.J. and SOUTH SAN FRANCISCO, Calif., May 18, 2011 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc.
WAYNE, N.J. and SOUTH SAN FRANCISCO, May 18, 2011 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc.
BARCELONA, April 20, 2011 /PRNewswire/ -- - Advancell has announced the initiation of a clinical phase IIb study of its treatment ATH008 for palmar-plantar erythrodysesthesia syndrome, or hand-foot syndrome, a painful side effect of chemotherapy.
WAYNE, N.J. and EMERYVILLE, Calif., Feb. 24, 2011 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Feb.
SAN ANTONIO, and SAN FRANCISCO, Dec.
THE WOODLANDS, Texas, Dec.
THE WOODLANDS, Texas, Dec. 8, 2010 /PRNewswire/ -- World-class investigators affiliated with US Oncology Research participated in studies that will be presented, discussed and displayed Dec.
- A serpent whose bite was fabled to produce intense thirst.